Editorial| Volume 117, ISSUE 11, P1851-1852, June 01, 2016

Should Physicians be Encouraged to use Generic Names and to Prescribe Generic Drugs?

      While using the brand names seems like a trivial issue at the outset, using these names is inherently problematic. Cardiovascular drugs remain the most commonly prescribed drugs by the physicians. The junior doctors are likely to introject practices of their seniors and consequently to reciprocate from the experiences learnt from their preceptors. Using the generic names may be one way to facilitate prescription of the generic drugs who have a better cost profile and similar efficacy than the more expensive branded drugs. In this editorial, we have outlined several arguments to suggest the importance of using the generic names in academic discussions and clinical documentation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ryskina K.L.
        • Pesko M.F.
        • Gossey J.T.
        • Caesar E.P.
        • Bishop T.F.
        Brand name statin prescribing ina resident ambulatory practice: implications for teaching cost-conscious medicine.
        J Grad Med Educ. 2014; 6: 484-488
        • Mehrotra A.
        • Reid R.O.
        • Adams J.L.
        • Friedberg M.W.
        • McGlynn E.A.
        • Hussey P.S.
        Physicians with the least experience have higher cost profiles than do physicians with the most experience.
        Health Aff. 2012; 31: 2453-2463
        • Kesselheim A.S.
        • Misono A.S.
        • Lee J.L.
        • Stedman M.R.
        • Brookhart M.A.
        • Choudhry N.K.
        • Shrank W.H.
        Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.
        JAMA. 2008; 300: 2514-2526
      1. Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group. National health care expenditure projections 2010–2020. Available at: Accessed on March 20, 2016.

        • Caverzagie K.J.
        • Iobst W.F.
        • Aagaard E.M.
        • Hood S.
        • Chick D.A.
        • Kane G.C.
        • Brigham T.P.
        • Swing S.R.
        • Meade L.B.
        • Bazari H.
        • Bush R.W.
        • Kirk L.M.
        • Green M.L.
        • Hinchey K.T.
        • Smith C.D.
        The internal medicine reporting milestones and the next accreditation system.
        Ann Intern Med. 2013 2; 158: 557-559
        • Kale M.S.
        • Bishop T.F.
        • Federman A.D.
        • Keyhani S.
        “Top 5” lists top $5 billion.
        Arch Intern Med. 2011; 17: 1856-1858
        • Jones P.
        • Kafonek S.
        • Laurora I.
        • Hunninghake D.
        Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
        Am J Cardiol. 1998; 81: 582-587
        • Stender S.
        • Schuster H.
        • Barter P.
        • Watkins C.
        • Kallend D.
        • MERCURY I Study Group
        Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
        Diabetes Obes Metab. 2005; 7: 430-438
        • Stuart B.
        • Davidoff A.
        • Erten M.
        • Gottlieb S.S.
        • Dai M.
        • Shaffer T.
        • Zuckerman I.H.
        • Simoni-Wastila L.
        • Bryant-Comstock L.
        • Shenolikar R.
        How Medicare Part D benefit phases affect adherence with evidence-based medications following acute myocardial infarction.
        Health Serv Res. 2013; 48: 1960-1977
        • Gagne J.J.
        • Polinski J.M.
        • Kesselheim A.S.
        • Choudhry N.K.
        • Hutchins D.
        • Matlin O.S.
        • Tong A.
        • Shrank W.H.
        Patterns and predictors of generic narrow therapeutic index drug use among older adults.
        J Am Geriatr Soc. 2013; 61: 1586-1591
        • Ryskina K.L.
        • Dine C.J.
        • Kim E.J.
        • Bishop T.F.
        • Epstein A.J.
        Effect of attending practice style on generic medication prescribing by residents in the clinic setting: an cbservational study.
        J Gen Intern Med. 2015; 30: 1286-1293